Multiple myeloma: open trials in South Korea

35 open trials have a site in South Korea. Registry data; only the trial team decides who can take part.

NCT05583617
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Trial Treatment · Phase 1/2 · Hoffmann-La Roche
Samsung Medical Center, Seoul · Severance Hospital, Yonsei University Health System, Seoul
Registry updated 2026-11-05
NCT05927571
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Trial Treatment · Phase 1 · Genentech, Inc.
The Catholic University of Korea - Seoul St. Mary's Hospital (Kangnam St. Mary's Hospital), Seocho · Asan Medical Center, Seoul · Samsung Medical Center - PPDS, Seoul · Seoul National University Hospital, Seoul · Severance Hospital, Yonsei University Health System, Seoul
Registry updated 2026-11-05
NCT07222761
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
Chonnam National University Hwasun Hospital, Hwasun · Samsung Medical Center, Seoul · Asan Medical Center, Seoul · Severance Hospital; Division of Hematology, Seoul · Seoul National University Hospital, Seoul · Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul · Ulsan University Hospital, Ulsan
Registry updated 2026-11-04
NCT07393282
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
Chonnam National University Hwasun Hospital, Hwasun · Severance Hospital, Yonsei University Health System, Seoul · Samsung Medical Center, Seoul · Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul · Seoul National University Hospital, Seoul · Asan Medical Center, Seoul · The Catholic University of Korea St Vincents Hospital, Suwon
Registry updated 2026-11-04
NCT04634552
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 2 · Janssen Research & Development, LLC
Chonnam National University Hwasun Hospital, Jeollanam-do · Severance Hospital, Yonsei University Health System, Seoul · Seoul National University Hospital, Seoul · Asan Medical Center, Seoul · The Catholic University of Korea Seoul St Marys Hospital, Seoul · Samsung Medical Center, Seoul
Registry updated 2026-11-03
NCT05552222
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Pusan National University Hospital, Busan · Dong-A University Hospital, Busan · Kyungpook National University Hospital, Daegu · National Cancer Center, Goyang-si · Chonnam National University Hwasun Hospital, Hwasun · Gachon University Gil Medical Center, Incheon · Asan Medical Center, Seoul · Severance Hospital, Yonsei University Health System, Seoul · Samsung Medical Center, Seoul · The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul · Seoul National University Hospital, Seoul
Registry updated 2026-11-03
NCT07665450
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
National Cancer Center, Gyeonggi-do · Seoul National University Bundang Hospital, Gyeonggi-do · Chonnam National University Hwasun Hospital, Jeollanam-do · The Catholic University of Korea Eunpyeong St Marys Hospital, Seoul · Asan Medical Center, Seoul · Seoul National University Hospital, Seoul · The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul · Samsung Medical Center, Seoul · Ulsan University Hospital, Ulsan
Registry updated 2026-11-03
NCT05519085
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Celgene
Pusan National University Hospital, Busan · Busan · Chonnam National University Hwasun Hospital, Hwasun · Hwasun · Seoul National University Bundang Hospital, Seongnam · Seongnam · Seoul National University Hospital, Seoul · Seoul · Seoul · Seoul · Samsung Medical Center, Seoul · Seoul · Asan Medical Center, Seoul · Severance Hospital, Yonsei University Health System, Seoul · The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul · Seoul
Registry updated 2026-10-30
NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Trial Treatment · Phase 3 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Seoul National University Hospital, Seoul · Samsung Medical Center, Seoul · The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul · Asan Medical Center, Seoul
Registry updated 2026-10-29
NCT05623020
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Trial Treatment · Phase 3 · Pfizer
Chonnam National University Hwasun Hospital, Hwasun-gun · Seoul National University Bundang Hospital, Seongnam · Seoul National University Hospital, Seoul · Samsung Medical Center, Seoul · The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul · Ewha Womans University Seoul Hospital, Seoul · The Catholic Univ. of Korea Seoul St. Mary's Hospital(Seoul St. Mary's Hospital), Seoul
Registry updated 2026-10-27
NCT03761108
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 1/2 · Regeneron Pharmaceuticals
National Cancer Center Korea, Goyang · Seoul National University Cancer Hospital, Seoul · The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul · Yonsei University College of Medicine (Severance Hospital), Seoul
Registry updated 2026-10-26
NCT04973605
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Trial Treatment · Phase 1/2 · BeOne Medicines
Samsung Medical Center, GangnamGu · The Catholic University of Korea, Seoul St Marys Hospital, SeochoGu · Severance Hospital Yonsei University Health System, SeodaemunGu · Seoul National University Hospital, Seoul · Asan Medical Center, SongpaGu
Registry updated 2026-10-26
NCT07735637
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Trial Treatment · Phase 3 · AstraZeneca
Seoul
Registry updated 2026-10-21
NCT04910568
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 1 · Genentech, Inc.
Samsung Medical Center, Seoul · Seoul National University Hospital, Seoul
Registry updated 2026-10-20
NCT05669989
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Trial Treatment · Phase 2 · Sanofi
Seoul · Seoul
Registry updated 2026-10-15
NCT04643002
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Trial Treatment · Phase 1/2 · Sanofi
Seoul · Seoul · Seoul · Seoul
Registry updated 2026-10-13
NCT07555938
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Trial Treatment · Phase 3 · Hoffmann-La Roche
Chonnam National University Hwasun Hospital, Jeollanam-do · Seoul National University Hospital, Seoul · Asan Medical Center, Seoul · Seoul St. Mary's Hospital, Seoul · Severance Hospital, Yonsei University Health System, Seoul · Samsung Medical Center, Seoul
Registry updated 2026-10-13
NCT05243797
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Trial Treatment · Phase 3 · European Myeloma Network B.V.
Chonnam National University Hwasun Hospital, Gwangju · Department of Oncology, Asan Medical Center, Seoul · Seoul National University Hospital, Internal Medicine, Seoul · Samsung Medical Center, Seoul · St. Mary's Hospital, Seoul · Severance hospital, Seoul
Registry updated 2026-10-07
NCT05730036
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
Inje University Busan Paik Hospital, Busan · Pusan National University Hospital, Busan · Chonnam National University Hwasun Hospital, Hwasun · Gachon University Gil Hospital, Incheon · jeonbuk National University Hospital, Jeonju · Severance hospital, Seoul · Seoul National University Hospital, Seoul · Seoul St. Marys Hospital, Seoul · Asan Medical Center, Seoul · Samsung Medical Center, Seoul
Registry updated 2026-10-07
NCT06698887
A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
Research · Bristol-Myers Squibb
Chonnam National University Hwasun Hospital, Hwasun · Asan Medical Center, Seoul · Samsung Medical Center, Seoul · Seoul National University Hospital, Seoul · The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul
Registry updated 2026-10-01
NCT07391657
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Trial Treatment · Phase 3 · AstraZeneca
Seoul
Registry updated 2026-09-29
NCT06500884
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Trial Treatment · Phase 2 · Janssen Research & Development, LLC
The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul · Seoul National University Hospital, Seoul · Samsung Medical Center, Seoul
Registry updated 2026-09-25
NCT07518186
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
National Cancer Center, Goyang-si · Seoul National University Bundang Hospital, Gyeonggi-do · Chonnam National University Hwasun Hospital, Hwasun · Samsung Medical Center, Seoul · Seoul National University Hospital, Seoul · The Catholic University of Korea Seoul St Marys Hospital, Seoul · Asan Medical Center, Seoul
Registry updated 2026-09-25
NCT07227311
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 2 · GlaxoSmithKline
Seoul · Ulsan
Registry updated 2026-08-25
NCT05020236
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Trial Treatment · Phase 3 · Pfizer
Pusan National University Hospital, Busan · Kyungpook National University Hospital, Daegu · Chonnam National University Hwasun Hospital, Hwasun-gun · Gachon University Gil Medical Center, Incheon · Seoul National University Bundang Hospital, Seongnam-si · Samsung Medical Center, Seoul · The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul · Asan Medical Center, Seoul · Seoul National University Hospital, Seoul
Registry updated 2026-08-24

All Multiple myeloma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error